AI and Genetics Research Identifies New Drug Targets and Candidates for Osteoarthritis Treatment

Researchers at University of Utah Health have combined genetic data from the Utah Population Database with AI-driven structural biology to identify a novel drug candidate, M04, for osteoarthritis. By targeting the WNK2 gene, which is linked to hereditary forms of the disease, the compound successfully reduced inflammatory gene activity and promoted cartilage cell health in laboratory models. While M04 represents a promising disease-modifying starting point, further preclinical testing in animal models is required to evaluate its safety and efficacy before human trials.

WNK2-targeted drug discovery

• ▪Researchers at the University of Utah Health filed a U.S. patent application covering compounds that inhibit WNK2 and their potential use in treating osteoarthritis.
• ▪Researchers at University of Utah Health identified WNK2, a gene and protein kinase, as a potential drug target for modifying osteoarthritis biology.
• ▪Researchers at the University of Utah Health are collaborating with the University of Utah Therapeutics Accelerator Hub to develop improved derivatives of WNK2-inhibiting compounds.

AI-driven compound screening

• ▪The AI-assisted virtual screening narrowed the initial library of half a million compounds down to slightly more than 50 predicted WNK2 inhibitors.
• ▪Scientists computationally simulated how approximately 500,000 chemical compounds would interact with the predicted WNK2 protein structure to identify potential inhibitors.
• ▪Researchers manually evaluated the AI-shortlisted compounds to select six candidates for laboratory testing in cell models.
• ▪Researchers used AI-based computational tools to predict the three-dimensional structure of the WNK2 protein.

M04 candidate compound effects

• ▪The candidate compound M04, selected from six tested molecules, demonstrated the strongest results in preventing osteoarthritis-like changes in human cartilage cells.
• ▪In laboratory cell models, the compound M04 reduced the activity of genes associated with inflammation while increasing the expression of genes linked to cartilage-cell health.
• ▪The compound M04 has not yet been tested in living organisms, leaving its toxicity, absorption, metabolism, and safety profile in humans unknown.
• ▪Preclinical testing in animal models is required to evaluate the safety, dosing, and efficacy of the compound M04 or its derivatives before clinical trials can begin.

Osteoarthritis molecular mechanisms

• ▪In osteoarthritis, inflammatory signals disrupt the balance of chondrocytes, increasing cartilage-degrading enzymes and suppressing repair genes.
• ▪Current approved treatments for osteoarthritis are limited to palliative pain management or joint replacement surgery, with no approved disease-modifying drugs available.
• ▪Osteoarthritis progression is driven by specific molecular signals and inflammatory pathways rather than being solely a consequence of mechanical wear and tear.

Utah family genetic studies

• ▪Genetic studies of Utah families with high rates of inherited osteoarthritis linked the progression of the disease to damaging changes and overactivity in the WNK2 gene.
• ▪Researchers utilized data from the Utah Population Database to identify rare variants of the WNK2 gene that underlie hereditary forms of osteoarthritis.